These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 37511055)

  • 1. Endothelin-1 in Health and Disease.
    Banecki KMRM; Dora KA
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endothelin system as target for therapeutic interventions in cardiovascular and renal disease.
    Eroglu E; Kocyigit I; Lindholm B
    Clin Chim Acta; 2020 Jul; 506():92-106. PubMed ID: 32151622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease.
    Böhm F; Pernow J
    Cardiovasc Res; 2007 Oct; 76(1):8-18. PubMed ID: 17617392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of endothelin in cardiovascular disease.
    Agapitov AV; Haynes WG
    J Renin Angiotensin Aldosterone Syst; 2002 Mar; 3(1):1-15. PubMed ID: 11984741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelins in cardiovascular biology and therapeutics.
    Dhaun N; Webb DJ
    Nat Rev Cardiol; 2019 Aug; 16(8):491-502. PubMed ID: 30867577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?
    Kirkby NS; Hadoke PW; Bagnall AJ; Webb DJ
    Br J Pharmacol; 2008 Mar; 153(6):1105-19. PubMed ID: 17965745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin receptor antagonists and cardiovascular diseases of aging.
    Love MP; McMurray JJ
    Drugs Aging; 2001; 18(6):425-40. PubMed ID: 11419917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19.
    Fisk M; Althage M; Moosmang S; Greasley PJ; Cope AP; Jayne DR; Galloway J; Hall F; Wilkinson IB; Ambery P; Cheriyan J
    Pulm Pharmacol Ther; 2021 Aug; 69():102035. PubMed ID: 33933611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12.
    Maguire JJ; Davenport AP
    Br J Pharmacol; 2014 Dec; 171(24):5555-72. PubMed ID: 25131455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical potential of endothelin receptor antagonists in cardiovascular medicine.
    Ferro CJ; Webb DJ
    Drugs; 1996 Jan; 51(1):12-27. PubMed ID: 8741230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin and endothelin antagonists: pharmacology and clinical implications.
    Lüscher TF; Wenzel RR
    Agents Actions Suppl; 1995; 45():237-53. PubMed ID: 7717186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of endothelins in human cardiovascular disease].
    Negrusz-Kawecka M
    Pol Merkur Lekarski; 2001 Nov; 11(65):444-6. PubMed ID: 11852820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin: 30 Years From Discovery to Therapy.
    Barton M; Yanagisawa M
    Hypertension; 2019 Dec; 74(6):1232-1265. PubMed ID: 31679425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension.
    Miyagawa K; Emoto N
    Ther Adv Cardiovasc Dis; 2014 Oct; 8(5):202-16. PubMed ID: 24990369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition.
    Kaoukis A; Deftereos S; Raisakis K; Giannopoulos G; Bouras G; Panagopoulou V; Papoutsidakis N; Cleman MW; Stefanadis C
    Curr Top Med Chem; 2013; 13(2):95-114. PubMed ID: 23470073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin receptor antagonists. Promising new agents in the management of cardiovascular disorders.
    Goddard J; Webb DJ
    Drugs R D; 1999 Jul; 2(1):1-12. PubMed ID: 10560541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin and endothelin receptors in the renal and cardiovascular systems.
    Vignon-Zellweger N; Heiden S; Miyauchi T; Emoto N
    Life Sci; 2012 Oct; 91(13-14):490-500. PubMed ID: 22480517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.
    Spieker LE; Noll G; Lüscher TF
    Am J Cardiovasc Drugs; 2001; 1(4):293-303. PubMed ID: 14728028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New expansion of endothelin research: perspectives for clinical application of endothelin-receptor antagonists].
    Goto K; Miyauchi T
    Nihon Yakurigaku Zasshi; 2003 Feb; 121(2):91-101. PubMed ID: 12616854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease.
    Schneider MP; Boesen EI; Pollock DM
    Annu Rev Pharmacol Toxicol; 2007; 47():731-59. PubMed ID: 17002597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.